Allogene Therapeutics, Inc. (ALLO) vs Altimmune, Inc. (ALT)
Allogene Therapeutics, Inc. and Altimmune, Inc. are both Biotechnology companies. Allogene Therapeutics, Inc. and Altimmune, Inc. are of similar size ($594.2M and $593.3M). Allogene Therapeutics, Inc. grew revenue faster over the last twelve months: 7,613.1% against 130.0%. Altimmune, Inc. has the higher net margin (0.00% vs −3,517.4%) and the higher return on invested capital (−34.3% vs −108.8%). Across the 16 metrics below, Altimmune, Inc. leads on 10 and Allogene Therapeutics, Inc. on 6.
Valuation
Profitability
| Metric | ALLO | ALT | Biotechnology median |
|---|---|---|---|
| Gross margin | 100.00% | 100.00% | 65.16% |
| Operating margin | (3,832.45%) | 0.00% | 0.00% |
| Net margin | (3,517.41%) | 0.00% | 0.00% |
| Free cash flow margin | (2,180.62%) | 0.00% | 0.00% |
| Return on equity | (42.39%) | (28.87%) | (57.72%) |
| Return on assets | (32.43%) | (25.58%) | (49.22%) |
| Return on invested capital | (108.81%) | (34.30%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack